Join Shattuck Labs for a virtual event to discuss comprehensive Phase 1 clinical data of SL-325, a potentially first-in-class DR3 blocking antibody, including safety, tolerability, pharmacokinetics, receptor occupancy, pharmacodynamic and immunogenicity results, as well as a pipeline update.

The event will feature presentations by members of Shattuck’s management team, including Taylor Schreiber, M.D., Ph.D., Chief Executive Officer, Lini Pandite, M.D., M.B.A., Chief Medical Officer, Suresh De Silva, Ph.D., Chief Scientific Officer, Michael Choi, M.D., Vice President of Clinical Development, and Andrew Neill, M.B.A., Chief Financial Officer.

A live question and answer session will follow the formal presentations.